Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease

Shaila P. Handattu, David W. Garber, Candyce E. Monroe, Thomas van Groen, Inga Kadish, Gaurav Nayyar, Dongfeng Cao, Mayakonda N. Palgunachari, Ling Li, G. M. Anantharamaiah

Research output: Contribution to journalArticlepeer-review

95 Scopus citations

Abstract

Recent evidence indicates that inflammation may significantly contribute to the pathogenesis of Alzheimer's disease (AD). Since the apo A-I mimetic peptide D-4F has been shown to inhibit atherosclerotic lesion formation and regress already existing lesions (in the presence of pravastatin) and the peptide also decreases brain arteriole inflammation, we undertook a study to evaluate the efficacy of oral D-4F co-administered with pravastatin on cognitive function and amyloid β (Aβ) burden in the hippocampus of APPSwe-PS1ΔE9 mice. Three groups of male mice were administered D-4F and pravastatin, Scrambled D-4F (ScD-4F, a control peptide) and pravastatin in drinking water, while drinking water alone served as control. The escape latency in the Morris Water Maze test was significantly shorter for the D-4F + statin administered animals compared to the other two groups. While the hippocampal region of the brain was covered with 4.2 ± 0.5 and 3.8 ± 0.6% of Aβ load in the control and ScD-4F + statin administered groups, in the D-4F + statin administered group Aβ load was only 1.6 ± 0.1%. Furthermore, there was a significant decrease in the number of activated microglia (p < 0.05 vs the other two groups) and activated astrocytes (p < 0.05 vs control) upon oral D-4F + statin treatment. Inflammatory markers TNFα and IL-1β levels were decreased significantly in the D-4F + statin group compared to the other two groups (for IL-1β p < 0.01 vs the other two groups and for TNF-α p < 0.001 vs control) and the expression of MCP-1 were also less in D-4F + statin administered group compared to the other two groups. These results suggest that the apo A-I mimetic peptide inhibits amyloid β deposition and improves cognitive function via exerting anti-inflammatory properties in the brain.

Original languageEnglish (US)
Pages (from-to)525-534
Number of pages10
JournalNeurobiology of Disease
Volume34
Issue number3
DOIs
StatePublished - Jun 2009

Bibliographical note

Funding Information:
This work was supported in part by Institute for the Study of Aging (S.P.H), NHLBI PO1 HL 34343 (D.W.G) and NIA AG 031846 (L.L). The behavioral studies were performed at Behavioral Assessment core, Dept. of Neurobiology, UAB which is supported by P30 NS47466.

Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.

Keywords

  • A-I mimetic
  • Amphipathic peptides
  • Amyloid β
  • Apo A-I
  • HDL

Fingerprint Dive into the research topics of 'Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this